The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Allogene Therapeutics Inc shares valued at $42,488 were sold by MESSEMER DEBORAH M. on Jun 18 ’24. At $2.28 per share, MESSEMER DEBORAH M. sold 18,641 shares. The insider’s holdings dropped to 166,765 shares worth approximately $0.39 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Humer Franz B sold 11,200 shares, netting a total of over 26,181 in proceeds. Following the sale of shares at $2.34 each, the insider now holds 255,253 shares.
Before that, Belldegrun Arie had added 1,724,137 shares to its account. In a trade valued at $4,999,997, the Director bought Allogene Therapeutics Inc shares for $2.90 each. Upon closing the transaction, the insider’s holdings increased to 1,724,137 shares, worth approximately $4.03 million.
As published in their initiating research note from Piper Sandler on May 31, 2024, Allogene Therapeutics Inc [ALLO] has been an Overweight and the price target has been revised to $11. Analysts at JMP Securities downgraded the stock from ‘”a Mkt outperform”‘ to ‘”a Mkt perform”‘ outlook in a report released in early January. As of January 05, 2024, Guggenheim has decreased its “Buy” rating to a “Neutral” for ALLO. Earlier on December 08, 2023, Citigroup initiated its rating. Their recommendation was “a Buy” for ALLO stock.
Analyzing ALLO Stock Performance
During the last five days, there has been a surge of approximately 4.93%. Over the course of the year, Allogene Therapeutics Inc shares have dropped approximately -27.10%. Shares of the company reached a 52-week high of $5.78 on 03/08/24 and a 52-week low of $2.18 on 06/18/24. A 50-day SMA is recorded $2.74, while a 200-day SMA reached $3.35. Nevertheless, trading volume fell to 2.98 million shares from 4.31 million shares the previous day.
Support And Resistance Levels for Allogene Therapeutics Inc (ALLO)
According to the 24-hour chart, there is a support level at 2.23, which, if violated, would cause prices to drop to 2.13. In the upper region, resistance lies at 2.44. The next price resistance is at 2.55. RSI (Relative Strength Index) is 41.96 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.02, which suggests the price will decrease in the coming days. Percent R is at 68.01%, indicating low price movement. Stochastics%K at holding indicates that the stock is to be held.
